Improving the outlook for TP53-aberrant CLL.
作者信息
Choi Michael Y
机构信息
University of California San Diego Moores Cancer Center.
出版信息
Blood. 2021 Nov 11;138(19):1785-1786. doi: 10.1182/blood.2021012759.
Abstract
摘要
相似文献
1
Improving the outlook for TP53-aberrant CLL.改善TP53异常的慢性淋巴细胞白血病的预后。
Blood. 2021 Nov 11;138(19):1785-1786. doi: 10.1182/blood.2021012759.
2
A comprehensive study of TP53 mutations in chronic lymphocytic leukemia: Analysis of 1287 diagnostic and 1148 follow-up CLL samples.全面研究慢性淋巴细胞白血病中的 TP53 突变：分析 1287 例诊断和 1148 例随访 CLL 样本。
Leuk Res. 2011 Jul;35(7):889-98. doi: 10.1016/j.leukres.2010.12.016. Epub 2011 Jan 13.
3
Aberrant nuclear p53 expression predicts hemizygous 17p (TP53) deletion in chronic lymphocytic leukemia.p53 核表达异常预示慢性淋巴细胞白血病中 17p（TP53）杂合性缺失。
Am J Clin Pathol. 2010 Jan;133(1):70-4. doi: 10.1309/AJCPEPX1C7HHFELK.
4
Prognostic and therapeutic stratification in CLL: focus on 17p deletion and p53 mutation.CLL 中的预后和治疗分层：关注 17p 缺失和 p53 突变。
Ann Hematol. 2018 Dec;97(12):2269-2278. doi: 10.1007/s00277-018-3503-6. Epub 2018 Oct 12.
5
Is the aberrant expression of p53 by immunocytochemistry a surrogate marker of TP53 mutation and/or deletion in chronic lymphocytic leukemia?免疫细胞化学检测到的p53异常表达是否为慢性淋巴细胞白血病中TP53突变和/或缺失的替代标志物？
Am J Clin Pathol. 2011 Jan;135(1):173-4. doi: 10.1309/AJCPFMV43IFPRTWK.
6
Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial.氟达拉滨难治性慢性淋巴细胞白血病（CLL）中p53通路缺陷的详细分析：在前瞻性临床试验中剖析17p缺失、TP53突变、p53-p21功能障碍和miR34a的作用
Blood. 2009 Sep 24;114(13):2589-97. doi: 10.1182/blood-2009-05-224071. Epub 2009 Jul 30.
7
PRIMA-1 cytotoxic effect correlates with p53 protein reduction in TP53-mutated chronic lymphocytic leukemia cells.PRIMA-1的细胞毒性作用与TP53突变的慢性淋巴细胞白血病细胞中p53蛋白的减少相关。
Leuk Res. 2020 Feb;89:106288. doi: 10.1016/j.leukres.2019.106288. Epub 2019 Dec 26.
8
Evaluation of TP53 mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: correlation with clinical outcome and gene expression profiling.采用 AmpliChip p53 研究检测评估慢性淋巴细胞白血病中的 TP53 突变：与临床结果和基因表达谱的相关性。
Genes Chromosomes Cancer. 2011 Apr;50(4):263-74. doi: 10.1002/gcc.20852. Epub 2011 Jan 13.
9
The percentage of cells with 17p deletion and the size of 17p deletion subclones show prognostic significance in chronic lymphocytic leukemia.17p 缺失细胞的百分比和 17p 缺失亚克隆的大小在慢性淋巴细胞白血病中具有预后意义。
Genes Chromosomes Cancer. 2019 Jan;58(1):43-51. doi: 10.1002/gcc.22692. Epub 2018 Nov 29.
10
aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics.慢性淋巴细胞白血病的畸变：诊断改进的临床意义概述。
Haematologica. 2018 Dec;103(12):1956-1968. doi: 10.3324/haematol.2018.187583. Epub 2018 Nov 15.
本文引用的文献
1
Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations.在伴有 TP53 缺失和/或突变的 CLL 患者中，联合靶向治疗后可获得持久缓解。
Blood. 2021 Nov 11;138(19):1805-1816. doi: 10.1182/blood.2020010484.
2
Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial.维奈托克联合奥滨尤妥珠单抗与苯丁酸氮芥联合奥滨尤妥珠单抗治疗初治慢性淋巴细胞白血病（CLL14）：一项多中心、开放标签、随机、3 期临床试验的随访结果。
Lancet Oncol. 2020 Sep;21(9):1188-1200. doi: 10.1016/S1470-2045(20)30443-5.
3
Ibrutinib for Chronic Lymphocytic Leukemia with Alterations.伊布替尼用于治疗伴有改变的慢性淋巴细胞白血病。
N Engl J Med. 2020 Jul 30;383(5):498-500. doi: 10.1056/NEJMc2005943.
4
Ibrutinib and Venetoclax for First-Line Treatment of CLL.伊布替尼联合维奈托克用于初治 CLL 患者。
N Engl J Med. 2019 May 30;380(22):2095-2103. doi: 10.1056/NEJMoa1900574.
5
Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial.维奈托克治疗伴有 17p 缺失的慢性淋巴细胞白血病患者：来自 II 期关键性试验全人群的结果。
J Clin Oncol. 2018 Jul 1;36(19):1973-1980. doi: 10.1200/JCO.2017.76.6840. Epub 2018 May 1.
6
CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia.CLL2-BXX 二期临床试验：慢性淋巴细胞白血病微小残留病灶消除的序贯靶向治疗。
Future Oncol. 2018 Mar;14(6):499-513. doi: 10.2217/fon-2017-0442. Epub 2018 Feb 21.
7
Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial.慢性淋巴细胞白血病的基因突变与治疗结果：CLL8 试验结果。
Blood. 2014 May 22;123(21):3247-54. doi: 10.1182/blood-2014-01-546150. Epub 2014 Mar 20.
8
Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies.宣告慢性淋巴细胞白血病的终结：新的一线治疗策略
Hematology Am Soc Hematol Educ Program. 2013;2013:138-50. doi: 10.1182/asheducation-2013.1.138.
9
The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness.TP53突变在慢性淋巴细胞白血病中的预后价值独立于17p13缺失：对总生存期和化疗难治性的影响
Clin Cancer Res. 2009 Feb 1;15(3):995-1004. doi: 10.1158/1078-0432.CCR-08-1630.
Zotero 插件